Two Days, Two Deals: AbbVie To Partner (Again) With Galapagos In Cystic Fibrosis
This article was originally published in The Pink Sheet Daily
AbbVie’s busy week continued when it unveiled a collaboration with Galapagos in cystic fibrosis Sept. 24, a day after it announced an inflammatory disease tie-up with Ablynx. AbbVie and Galapagos already are partnered under a 2012 deal in rheumatoid arthritis and Crohn’s disease.
You may also be interested in...
Start-up fundraising for Q3 2013 totaled $559.4 million, down from last quarter’s big rally ($907.2 million) but still up from the sluggish first quarter ($398.7 million). More than half of that money went to biopharma companies, a group which also received investments through alliances with equity provisions.
Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause
The discovery in 1989 of the underlying genetics causing cystic fibrosis was expected to spur broad development of disease-modifying therapies. As of 2013, however, only one such drug is on the market, for a small subset of CF patients, and a few other candidates are in clinical development.
As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.